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ABSTrACT
The aim of the article is to summarize the current 
knowledge on the phenomenon of fear of hypogly-
caemia and its impact on the metabolic control and 
well-being of the population of diabetic patients. The 
article proposes a description of clinical criteria use-
ful for the diagnosis of the fear of hypoglycaemia in 
a non-normative and harmful form. Therapeutic direc-
tions are presented that have been proven effective 
in the recent years in reducing the level of maladap-
tive fear of hypoglycaemia, while also protecting 
the mental health of the patients. Despite extensive 
knowledge and numerous clinical trials undertaken in 
other countries, further research on diabetes-related 
anxiety disorders in Polish patients is needed. It is also 
advisable to create a database of culturally adapted 
management protocols for specialists that could in-
crease the quali ty and effectiveness of the assistance 
provided in the outpatient health care. (Clin Diabetol 
2020; 9; 6: 479–484)
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Introduction
Hypoglycaemia has always been an important issue 
in the scientific discussions regarding the management 
of diabetes [1]. Hypoglycaemia is often described as 
one of the greatest barriers on the patient’s path to 
normoglycaemia and a risk factor that might lead to the 
development of life-threatening complications [2, 3]. 
The experience of hypoglycaemia may be incidental 
but very unpleasant, leading to lifelong memories of 
the event.
For reasons that are justified, the occurrence and 
perspective of experiencing hypoglycaemia may elicit 
strong emotions in patients. Fear of hypoglycaemia has 
its legitimate background and an adaptive meaning. 
Careful self-management and appropriate decisions 
when managing insulin therapy may successfully 
protect patients from hypoglycaemia and related con-
sequences. However, fear is associated with some risk. 
Although it is a universal, primary and natural experi-
ence not only for humans, in specific settings it may 
acquire pathological features, initiate maladaptive 
mechanisms, and severely disorganize human’s life. 
For good reason, fear has been termed the backbone 
of the most syndromes known in the contemporary 
psychiatric practice [4]. 
Multiple clinical studies have performed regarding 
the fear of hypoglycaemia and its effect on the thera-
peutic process, mental health, and subjective wellbe-
ing of the diabetic population. Unfortunately, fear of 
hypoglycaemia remains very difficult to identify in the 
inpatient and outpatient practice, as no clear criteria 
are available to diagnose it in its non-normative, harm-
ful form. However, the most troublesome is the lack of 
a culturally adapted management protocol that would 
be dedicated to that issue.
Hypoglycaemia — diagnosis  
and risk factors
Hypoglycaemia is a common phenomenon in 
diabetic patients treated with insulin and oral glucose-
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-lowering drugs such as sulphonylureas [5]. It has been 
estimated that hypoglycaemia, both symptomatic and 
asymptomatic, may occur thousands of times during 
the lifespan of an average patient [6]. 
According to the Polish Diabetes Association guide-
lines [7], hypoglycaemia should be categorized using 
three glycaemic/symptomatic thresholds. Alert blood 
glucose level (level 1) is defined as values below 70 mg/dL 
(3.9 mmol/L) regardless of the presence of absence of 
concomitant symptoms. Clinically significant hypogly-
caemia (level 2) is defined as blood glucose level below 
54 mg/dL (3.0 mmol/L). Severe hypoglycaemia (level 3) 
is diagnosed based on clinical symptoms associated 
with severe cognitive dysfunction, without any blood 
glucose level criterion. A third party intervention is 
required to terminate a severe hypoglycaemia episode.
At the physiological level, early response to hypo-
glycaemia involves activation of the autonomic nervous 
system. Early neurovegetative (adrenergic) symptoms 
include pallor, muscle tremor, profuse sweating, dizzi-
ness and/or headache, anxiety, and nervousness. Later, 
due to shortage of glucose in the central nervous sys-
tem cells, neuroglycopenia ensues which is associated 
with cognitive dysfunction (e.g., confusion, disorienta-
tion, attention and memory deficits) and neurological 
symptoms (slurred speech, irrational or uncontrolled 
behaviours, loss of consciousness, seizures, nystagmus, 
reduced responsiveness to stimuli) [8]. The experience 
and recognition of the above clinical symptoms of hy-
poglycaemia may show large interindividual variation 
in the diabetic patient population [9].
The likelihood of an adverse fall in blood glucose 
level depends on many variables. The major iatrogenic 
risk factor are inadequate, excessive or maladjusted 
doses of insulin (or a substance that stimulates insu-
lin release) in relation to the individual requirement, 
dietary intake (exogenous glucose) and/or planned 
physical activity [10].
The risk of hypoglycaemia is increased in the set-
tings of reduced endogenous glucose production (e.g., 
following excessive alcohol intake or in liver failure), 
increased carbohydrate utilization, or reduces hepatic 
glycogen stores (e.g., during intense exercise or diet-
ing). Additional risk settings include increased insulin 
sensitivity (e.g., during or immediately after exercise or 
during nocturnal rest) and reduced insulin clearance 
(e.g., in progressive renal failure) [11, 12]. Other risk 
factors are diabetes duration and type, patient age, 
reduced hypoglycaemia awareness, and past experience 
of severe hypoglycaemia [13–16].
Recurrent hypoglycaemia is associated with a risk 
of irreversible changes and may lead to further compli-
cations. Particular risks are associated with cardiovas-
cular changes and events induced by hypoglycaemia. 
Cardiovascular events may increase the likelihood of 
sudden cardiac death [13, 17, 18]. Severe hypogly-
caemia may affect the vascular system and activate 
prothrombotic, proinflammatory and proatherogenic 
mechanisms [19]. Recurrent hypoglycaemia attenuates 
symptomatic and hormonal responses to the episodes 
of low blood glucose level, leading to the development 
of hypoglycaemia unawareness syndrome. The latter is 
characterized by a reduced or absent ability to identify 
the onset of hypoglycaemia despite blood glucose level 
lowering to the values usually associated with warning 
symptoms [20]. This significantly increases the risk of 
severe hypoglycaemia [14].
Hypoglycaemia has a major effect on worsened 
wellbeing and reduced quality of life of diabetic pa-
tients [21, 22]. It may also result in reduced profes-
sional productivity, increased absence from work, and 
increased overall costs related to health status [23]. 
Severe and recurrent hypoglycaemia may increase the 
overall level of anxiety [24]. Unfortunately, an increas-
ing severity of anxiety is not always a desirable effect 
in these settings.
fear of hypoglycaemia — from the norm 
to pathology
In general, anxiety may be described as a condition 
of unpleasant discomfort, tension and/or unrest which 
is accompanied by an increased level of excitation or 
even specific somatic experiences such as palpitation, 
tremor, and dyspnoea. In contrast to fear which is felt in 
response to a defined, recognizable stimulus, anxiety is 
an anticipatory reaction to an impending stimulus (may 
arise without a clear cause). From the functional perspec-
tive, human ability to feel anxiety is of major importance 
when safety of an individual is at stake — the protective 
or defensive reaction is a priority to ensure survival and 
protection of what is the most valuable [25].
Anxiety is a very complex phenomenon which 
depends on genetic factors, environmental influences, 
and combination of both [26]. It is an adaptive signal-
ling-protective mechanism which is important from the 
perspective of the theory of evolution [27]. Already at 
the subconscious level, anxiety organizes perception 
systems, participates in processing information from 
the sensory channels, directs attention processes (e.g., 
selection) and memory, engages systems responsible for 
learning and leads to activation of body’s physiological 
reactions — involuntary but dependent on the form of 
perceived danger. Most importantly, anxiety contributes 
much to the overall decision process in the context of 
choosing the best available behaviour in the situation 
of a perceived danger [28]. 
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Clinically, non-normative anxiety is recurrent, 
persistent, and/or objectively inadequate for a given 
situation [27]. The criterion of inadequacy for a given 
situation may involve two forms — either excessive 
anxiety for a low level of danger (e.g., phobia), or 
inadequately low anxiety for a high level of danger 
(e.g., denial).
In the context of fear of hypoglycaemia, its adap-
tive nature depends on the criterion of adequacy 
of the felt anxiety in relation to the objective risk of 
hypoglycaemia [29]. Inadequately high level of anxi-
ety in relation to a low risk of hypoglycaemia will lead 
to escalation of protective and avoidance behaviours. 
In this situation, the actual danger for the patient 
is chronic hyperglycaemia induced by interventions 
aimed to protect from blood glucose level lowering. 
Conversely, inadequately low level of anxiety in relation 
to a high risk of hypoglycaemia may also create danger. 
In this case, hypoglycaemia itself will be a major risk for 
the patient, as the patient will not try to protect from 
it, and with time he or she will not even recognize its 
symptoms due to habituation. 
Psychopatologically, anxiety disorder is said to oc-
cur when the subjective severity of anxiety, its intensity 
and frequency lead to disorganization of the indivi-
dual’s life, resulting in suffering [30]. The diabetes self-
management process itself should protect the patient 
from suffering, and at the same time allow active social 
and professional functioning tailored to the patient’s 
needs, as well as pursuing pastime hobbies and other 
activities aimed at achieving individual wellbeing and 
adequate mental health status. Unfortunately, inade-
quate fear of hypoglycaemia and associated behaviours 
generate secondary effects in many areas important 
for the patient, affecting the subjective assessment of 
quality of life and the severity of depression in both 
adults and children [30].
Diagnosis of non-adaptive fear  
of hypoglycaemia
Inadequate fear of hypoglycaemia may be identi-
fied based on observation and history taking [32] and 
may be reflected by laboratory test results (haemo-
globin A1c [HbA1c] level) [33]. Studies on the relation 
between fear of hypoglycaemia and metabolic control 
of diabetes provided strong evidence that fear may 
motivate patients to actions directed at preventing hy-
poglycaemia, thus leading to chronic hyperglycaemia. 
Obviously, this association is much more complex and 
involves interactions with many variables, and thus 
not all studies may be expected to confirm the relation 
between metabolic control and the severity of fear of 
hypoglycaemia [29, 34]. For example, some patients 
may present with adequate metabolic control, while 
fear of hyperglycaemia may be reflected in excessive 
blood glucose level measurements, home isolation, and 
lifestyle restrictions that preclude professional activities.
The risk of developing non-normative fear of hypo-
glycaemia is associated with many patient personality 
features, such as the overall severity of the anxiety as 
a general feature and the level of neuroticism [29]. 
However, as shown in multiple studies, the strongest 
risk factor is patient’s previous experience of hypogly-
caemia. Fear of hypoglycaemia is associated with both 
the severity and frequency of previous hypoglycaemia 
episodes [34, 35]. This phenomenon affects not only 
diabetic patients but also their close persons (e.g., 
family members, caretakers of minors with diabetes, 
partners) [36, 37]. 
Based on the current studies, one of the best known 
self-descriptive tools to measure the severity of fear of 
hypoglycaemia is the Hypoglycaemia Fear Survey (HFS 
and HFS-II) developed by Cox, Irvine, Gonder-Frederick 
et al. [38]. This questionnaire includes 33 items measur-
ing the behavioural and affective-cognitive dimensions 
of the fear of hypoglycaemia. Other screening tools 
have also been developed during the last 20 years, in-
cluding the Quick Screening for Fear of Hypoglycaemia 
(QSFH) [39], an abbreviated and improved version of 
HFS known as the Fear of Hypoglycaemia Scale (FH-15) 
[40], and the paediatric version known as the Children’s 
Hypoglycaemia Index (CHI) [41]. Despite their promising 
psychometric properties, neither HFS-II, its abbreviated 
versions, nor QSFH and CHI have been adapted to or 
validated in the Polish population. As result, it is dif-
ficult to use them as screening tools in the outpatient 
diabetes care settings.
Further studies are recommended to identify the 
special at-risk group in which the problem of non-nor-
mative fear of hypoglycaemia might be revealed during 
the therapeutic process. As indicated by Böhme et al. 
[42], as healthcare professionals we still do not know 
enough about our patients, and our patients are too 
often reluctant to disclose their fear of hypoglycaemia.
Therapeutic directions in the  
management of fear of hypoglycaemia
Currently, the main therapeutic model in the mana-
gement and prevention of recurrent hypoglycaemia in 
the context of non-normative fear of hypoglycaemia 
is holistic education and increasing awareness of indi-
viduals at risk of hypoglycaemia in regard to the risk, 
diagnosis and management of future hypoglycaemia 
episodes. Studies confirmed a significant effect of 
education on self-monitoring of blood glucose and 
avoidance of hypoglycaemia [43, 44]. 
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The best known psychoeducation protocols target-
ed at hypoglycaemia include the Hypoglycaemia Antici-
pation, Awareness and Treatment Training (HAATT), Hy-
POS, and Blood Glucose Awareness Training II (BGAT-2) 
[45–47]. The common feature of these programs is 
combining home-based self-monitoring (e.g., keeping 
a hypoglycaemia diary) with group sessions over several 
weeks targeted at patient education covering the prin-
ciples of insulin therapy management, planning actions 
directed at maintaining normoglycaemia, and coping 
with extreme situations (e.g., hypoglycaemia and 
ketoacidosis). Studies on these protocols showed that 
they are satisfactorily effective in increasing patients’ 
hypoglycaemia awareness and reducing the number 
of hypoglycaemia episodes. In addition, the BGAT-2 
program was also shown to be effective in reducing 
fear of hypoglycaemia and depressive symptoms and 
improving the perceived quality of life in patients with 
diabetes type 1 subjected to this intervention [48].
Fear of hypoglycaemia may also be addressed with 
cognitive-behavioural therapy (CBT)-based psychothe-
rapy programs which were shown to be highly effective 
in the treatment of a wide spectrum of anxiety disorders 
[49]. The 8-week StyrKRAFT i Ditt Liv© (Power to Choose 
your Direction) program developed by Amsberg, Ander-
bro et al. [50], consisting of 2-hour CBT group sessions 
and support and monitoring interventions following 
the end of group sessions, was shown to be associated 
with significantly lower HbA1c levels in the intervention 
group at 8, 24 and 48 weeks after program conclusion. 
In addition, significant beneficial differences between 
the CBT and control group were also noted in the 
mean assessment of wellbeing, perceived distress, 
level of anxiety, and severity of depressive symptoms 
[51]. Similar effects of individual CBT psychotherapy 
were shown in a case study by O’Donnell et al. [52]. 
Graded exposition combined with CBT interventions 
employed in a patient with diagnosed fear of hypogly-
caemia resulted in a reduced fear of hypoglycaemia and 
lower frequency of protective behaviours targeted at 
maintaining high blood glucose levels during the day. 
As a result, the intervention improved self-monitoring 
of blood glucose parameters and contributed to bet-
ter mental functioning of the patients (reduction in 
generalized anxiety and depression).
An important component of the above psychoedu-
cation programs and CBT interventions is an access to 
modern blood glucose monitoring technologies. These 
solutions play an important role, providing biofeedback 
to the patients’ therapeutic efforts, which undoubtedly 
had an effect on the final therapy effect. For example, the 
HAATT protocol used Accucheck Easy BG, Medtronic’s 
CGMS Gold was used in group CBT, and continuous 
glucose monitoring was used in the CBT case study. 
However, caution is advised in the available literature 
regarding the use of continuous glucose monitoring 
systems (CGMS) in patients suspected of anxiety dis-
orders, as this may paradoxically increase their anxiety 
and lead to treatment discontinuation [52]. 
Unfortunately, despite many successes in the 
international arena, there are no Polish adaptations 
of programs such as HAATT, HyPOS, and BGAT-2 and 
thus, despite large demand, they are not available for 
the Polish population of diabetic patients. Developing 
such culturally adapted psychoeducation protocols is 
a desired future direction of work for the healthcare 
community involved in diabetes care and education. 
Promising results may be obtained with CBT-based 
psychotherapy. It is important, however, that these 
interventions be developed based on cooperation of 
certified psychotherapists and a wide community of 
specialists involved in diabetes care and education. 
Controlled access to modern technologies may be 
a helpful addition to the psychoeducation process and 
therapy, allowing the patients to monitor changes 
which highlight the effect of their decisions on the 
ultimate biopsychophysical outcomes.
Conclusions
Normative fear of hypoglycaemia is consistent with 
situations where a patient is able to self-identify the 
existing hypoglycaemia based on clinical symptoms 
and/or use of blood glucose level measurement tech-
nologies, which allows an adequate response to restore 
normoglycaemia. Adaptive fear of hypoglycaemia will 
also motivate the patient to plan future behaviours with 
the aim of maximizing the likelihood of maintaining 
normoglycaemia and minimizing the occurrences of 
both hypo- and hyperglycaemia. It will play a regulatory 
role in terms of daily functioning of the patient (his or 
her professional, personal, and social activities), his 
or her physical and mental health, and the subjective 
wellbeing and satisfaction from life.
Non-normative fear of hypoglycaemia may be 
diagnosed if it is inadequate to the individual risk of 
hypoglycaemia. It will induce a harmful effect on the 
patient’s health which may be identified by observa-
tion, history taking and/or results of self-monitoring 
of blood glucose. The pathological component of 
fear of hypoglycaemia is said to be present when the 
non-adaptive level of fear and its consequences pose 
a threat for the patients’ wellbeing and mental health, 
leading to a subjective suffering.
The diagnosis of harmful, non-normative fear of 
hypoglycaemia in the outpatient or inpatient setting 
should be preceded by detailed history taking regard-
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ing the previous disease course and patient actions in 
the context of hypoglycaemia. Patients presenting with 
severe fear of hypoglycaemia should receive adequate 
medical and psychoterapeutic care. The issue of diag-
nosing and managing fear of hypoglycaemia should 
be an inherent component of the recommendations 
for healthcare personnel caring for diabetic patients. 
Prompt intervention and help offered to patients with 
non-normative fear of hypoglycaemia may contribute 
to better treatment outcomes and preservation of what 
is most important in the patient’s life. Further research 
is needed on the possible directions of help and support 
for Polish diabetic patients affected by non-normative 
fear of hypoglycaemia.
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